Background
==========

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid tumors, and carries an extremely poor prognosis \[[@B1]\]. Although the management and treatment of patients with pancreatic cancer have improved over the last few decades, the overall 5-year survival rate remains less than 5% \[[@B2]\]. Long-term survival is rare, even in patients who undergo a histologically curative operation, with overall 5-year survival rates ranging from 10% to 25% \[[@B3],[@B4]\]. The high mortality rate associated with pancreatic cancer is known to be due to extensive invasion into surrounding tissues and metastasis to distant organs at the time of diagnosis (or even after a curative operation); however, the molecular mechanisms of the highly aggressive nature of PDAC remains unclear \[[@B5]\].

Previous studies have shown an association between progression of PDAC and overexpression of several growth factors (and their receptors) including insulin-like growth factor (IGF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF) \[[@B6]-[@B8]\]. Most of the cellular effects of IGF-I and IGF-II are mediated by the IGF-I receptor (IGF1R). Binding of the ligand to IGF1R leads to tyrosine phosphorylation of the major receptor substrate followed by activation of certain downstream signaling cascades \[[@B9]\]. The IGFs have been implicated through IGF1R in the pathogenesis, cell proliferation, and cell survival of many cancers \[[@B10],[@B11]\]. IGF-1, which is produced primarily by the liver, is known to play an important role in the regulation of cell proliferation, differentiation, and apoptosis \[[@B10]-[@B12]\]. Clinical studies in colorectal, esophageal, and pancreatic cancers have shown that IGF1R signaling correlates with increased tumor growth and malignancy in vitro \[[@B8],[@B13],[@B14]\].

The IGF system is a complex network of growth factors (IGF-I and IGF-II), cell surface trans-membrane receptors (IGF1R), and high affinity IGF-binding proteins (IGFBPs) that play an important role in normal cellular growth and development, and disruption of the balance of this system has been implicated in the etiology and progression of breast and other cancers \[[@B15]\]. Activation of the IGF system stimulates proliferation, differentiation, angiogenesis, metastasis, survival, and resistance to anticancer therapies in many cancers \[[@B16]\], supporting the idea that the IGF system is an attractive therapeutic target. The biological actions of IGFs are modulated by a family of IGFBPs in the local tissue microenvironment \[[@B17],[@B18]\]. IGFBP3 is part of the family of six IGFBPs that bind the peptide growth factors IGF-I and IGF-II with high affinity and regulate their bioactivity \[[@B19]\]. IGFBP3 is the most abundant IGFBP, being present in almost all tissues. IGFBP3 inhibits IGF1R mediated signaling by preventing the interaction of IGFs with IGF1R. IGFBP3 regulates the mitogenic action of IGFs or inhibits their antiapoptotic effects through IGF-dependent and IGF-independent mechanisms \[[@B20],[@B21]\]. However, there are few evidences of an association between IGFBP3 and enhanced cell proliferation. These findings have encouraged investigators to investigate whether IGFBP3 plays a positive or negative role in IGF-promoted tumor development.

Although serum levels of IGF-I are generally considered to be a positive risk factor for development of colorectal cancer, the role of IGFBP3 appears less clear. Both the inhibition and activation of cellular functions by these proteins have been demonstrated to depend on cell type \[[@B22]\]. The present study examined IGF1R and cell surface-associated IGFBP3 expression in patients with pancreatic cancer.

Methods
=======

Patients
--------

A total of 122 patients who had undergone resection of a primary pancreatic tumor at the Department of Surgical Oncology, Osaka City University Hospital were included. The pathologic diagnoses and classifications were made according to the UICC Classification of Malignant Tumors \[[@B23]\]. No patients had hematogenous metastases or peritoneal dissemination before surgery. Histological findings are according to the classification of pancreatic carcinoma in Japan Pancreas Society \[[@B24]\]. Patients' characteristics are shown in Table  [1](#T1){ref-type="table"}. The median age of patients was 68 years (range 33--84 years). A total of 79 patients (64.8%) died during the follow-up period, and the majority of patients were male (67.2%), and Stage II (78.7%). The observation period is overall survival time that was set in days as the period from the time of resection until the time of death. The study protocol conformed to the ethical guidelines of the Declaration of Helsinki (1975). This study was approved by the Osaka City University ethics committee. Informed consent was obtained from all patients prior to entry.

###### 

Patients' clinicopathological characteristics

  **Clinicopathologic characteristics**   **n = 122**
  --------------------------------------- -------------
  Gender                                   
     Male                                 66
     Female                               56
  Age (years)                              
     Median                               68
     Range                                33-84
  Tumor location                           
     proximal                             81
     distal                               41
  Tumor differentiation                    
     Grade 1                              35
     Grade 2                              67
     Grade 3                              17
     Grade 4                              3
  Tumor stromal volume                     
     Medullary type (med)                 1
     Intermediate type (int)              85
     Scirrhous type (sci)                 36
  T category                               
     T1                                   11
     T2                                   15
     T3                                   84
     T4                                   12
  N category                               
     N0                                   56
     N1                                   66
  Stage                                    
     I                                    15
     II                                   95
     III                                  12
     IV                                   0

TNM classification is according to the International Union against Cancer (UICC, 2003).

Medullary type (med): scanty stroma, Intermediate type (int): the quantity of stroma is intermediate between the two above types, Scirrhous type (sci): abundant stroma.

Immunohistochemical techniques
------------------------------

Sections of paraffin-embedded tissue (4-μm thick) were prepared. Immunohistochemical staining for IGF1R and IGFBP3 was performed using the avidin-biotin-peroxidase complex method. In brief, the deparaffinized and hydrated tissues were heated for 10 min at 105°C in Target Retrieval Solution (Dako, Carpinteria, CA, USA). Then, the slides were allowed to cool for 20 min on a lab bench in the Target Retrieval Solution at 25°C. The slides were incubated overnight at 4°C with 5 μg/mL of antihuman IGF1R mouse monoclonal antibody (Abcam, Cambridge, MA, USA) and 5 μg/mL of antihuman IGFBP3 rabbit polyclonal antibody (Abcam, Cambridge, MA, USA).

Immunohistochemical determination
---------------------------------

All slides were examined by two of the authors who were blinded to clinical data. The final evaluation of ambiguous cases was decided after discussion between the two authors. For determination of IGF1Rand IGFBP3 protein immunoreactivity, the cytoplasm and membrane staining intensity and patterns were evaluated according to the following scale. Immunoreactivity for IGF1R was evaluated in the neoplastic epithelial cells using a combined scoring system based on the sum of the staining intensity and the percentage of positive cells. Scores from 0--3 were given for the staining intensity and the percentage of positive cells as follows: score of 0, no staining is observed, or is observed in less than 10% of the tumor cells; score of 1+, weak staining is detected in 10% or more of the tumor cells; score of 2+, moderate staining is observed in 10% or more of the tumor cells; and score of 3+, strong staining is observed in 10% or more of the tumor cells. Scores of 0 and 1+ were considered to be negative for IGF1R overexpression, while scores of 2+ and 3+ were considered to be positive for IGF1R overexpression. Immunoreactivity for IGFBP3 was evaluated in the neoplastic epithelial cells using a combined scoring system based on the sum of the staining intensity and the percentage of positive cells. For determination of IGFBP3 protein immunoreactivity, staining of antibody was considered positive if \>10% of tumor cells were stained.

Statistical analysis
--------------------

The χ^2^-test or Fisher's exact test was used to determine the significance of the differences between the covariates. Survival durations were calculated using the Kaplan-Meier method and were analyzed by the log-rank test to compare the cumulative survival durations in the patient groups. The Cox proportional hazards model was used for the univariate and multivariate analyses. All analyses were performed using SPSS software (SPSS Japan, Tokyo, Japan). A *P*-value \< 0.05 was considered to represent statistical significance.

Results
=======

Expression of IGF1R and IGFBP3
------------------------------

Tumors with positive IGF1R protein showed cytoplasmic staining. Typical images of positive immunostaining for IGF1R in cancer cells are shown in Figure  [1](#F1){ref-type="fig"}A. Overall, seven cases had a score of 0, 69 cases had a score of 1+, 23 cases had a score of 2+, and 27 cases had a score of 3+. Thus, 50 cases (41%) were positive for IGF1R overexpression. Most of the positive staining was observed in the cytoplasm, while two cases showed positive staining in both membranes and cytoplasm. In contrast, no or weak staining was seen in the cytoplasm of pancreatic duct cells and acinar cells, and there was no staining in the membranes. Figure  [1](#F1){ref-type="fig"}B shows a representative picture of IGFBP3 staining. IGFBP3 was mainly expressed in the cytoplasm of cancer cells. Eighty-five cases of PDAC showed negative IGFBP3 expression, whereas 37 cases were positive.

![**IGF1R and IGFBP3 expression in pancreatic cancer. A**, Representative IGF1R staining quantified with scores of 0 to 3+ according to staining intensity. (Original magnification X 200). IGF1R was mainly expressed in the cytoplasm of pancreatic cancer cells. **B**, IGFBP3 was expressed in the cell membrane and the cytoplasm of pancreatic cancer cells.](1471-2407-13-392-1){#F1}

Clinicopathological association of IGF1R and IGFBP3 expression
--------------------------------------------------------------

Table  [2](#T2){ref-type="table"} shows the association of clinicopathological characteristics and IGF1R or/and IGFBP3 expression. IGF1R expression had a significant association with histological grade (Fisher's exact test, *p* = 0.037). Stromal volume tended to be more abundant in PDAC with IGF1R overexpression, but no significant difference was observed (χ^2^ test, *p* = 0.087). IGFBP3 expression had a significant association with tumor location (χ^2^ test, *p* = 0.023), and a significant inverse association with venous invasion (Fisher's exact test, *p* = 0.037). IGFBP3 expression tended to be frequent in differentiated PDAC in histological grade, but no significant difference was observed (χ^2^ test, *p* = 0.082).

###### 

**Association between IGF1R** &**IFGBP3 expression and clinicopathological factors in resectable pancreatic cancer**

                                    **IGF1R expression**   **IGFBP3 expression**   **Both IGF1R (+) and IGFBP3 (−)**                              
  -------------------------------- ---------------------- ----------------------- ----------------------------------- ---- ---- ------- ---- ---- -------
                Age                                                                                                                                   
                 \<60                        7                      18                                                 10   15           3    22      
                  ≧60                        43                     54                           0.139                 27   70   0.238   29   68   0.07
               Gender                                                                                                                                 
                 Male                        25                     31                                                 15   41           16   40      
                Female                       25                     41                           0.449                 22   44   0.433   16   50   0.588
             T category                                                                                                                               
                T1, T2                       9                      17                                                 7    19           3    23      
                T3, T4                       41                     55                           0.457                 30   66   0.670   29   67      
             N category                                                                                                                            0.077
                  N0                         23                     33                                                 20   36           14   42      
                  N1                         27                     39                           0.986                 17   49   0.233   18   48   0.776
               Stage                                                                                                                                  
                   I                         4                      11                                                 5    10           0    15      
               II & III                      46                     61                                                 32   75           32   75      
           Tumor location                                                                        0.273                           0.787             0.011
               proximal                      31                     50                                                 30   51           18   63      
                distal                       19                     22                                                 7    34           14   27      
       Tumor differentiation                                                                     0.392                           0.023             0.157
               Grade1, 2                     46                     56                                                 34   68           28   74      
              Grade 3, 4                     4                      16                           0.037                 3    17   0.082   4    16   0.588
         Lymphatic invasion                                                                                                                           
               negative                      24                     42                                                 19   47           15   51      
               positive                      26                     30                           0.260                 18   38   0.688   17   39   0.340
         Arterial invasion                                                                                                                            
               negative                      43                     67                                                 33   77           27   83      
               positive                      7                       5                           0.198                 4    8    0.754   5    7    0.200
          Venous invasion                                                                                                                             
               negative                      45                     62                                                 36   71           28   79      
               positive                      5                      10                           0.52                  1    14   0.037   4    11   0.967
   Intrapancreatic nerve invasion                                                                                                                     
               negative                      21                     38                                                 16   43           16   43      
               positive                      29                     34                           0.241                 21   42   0.456   16   47   0.829
        Tumor stromal volume                                                                                                                          
               med & int                     31                     55                                                 27   59           19   67      
                  sci                        19                     17                           0.087                 10   26   0.692   13   23   0.108
         IGFBP3 expression                                                                                                                            
               negative                      32                     53                                                                                
               positive                      18                     19                           0.256                                                

Medullary type (med): scanty stroma, Intermediate type (int): the quantity of stroma is intermediate between the two above types, Scirrhous type (sci): abundant stroma.

Relationship between clinicopathological features and tumors with IGF1R-positive and IGFBP3-negative expression
---------------------------------------------------------------------------------------------------------------

Among the 50 patients with positive IGF1R expression, 32 patients (64.0%) had negative IGFBP3 expression. Tumors with IGF1R-positive and IGFBP3-negative expression (n = 32) were significantly frequently found to have Stage II and III cancer (χ^2^ test, *p* = 0.011) compared to the other groups (n = 90). Tumors with IGF1R-positive and IGFBP3-negative expression tended to be in older patients (Fisher's exact test, *p* = 0.07) and advanced T stage (χ^2^ test, 0.077). Among the 72 patients with negative IGF1R, 53 patients (73.6%) showed negative IGFBP3 expression, whereas 19 patients (26.4%) had positive IGFBP3 expression. No association was found between IGF1R and IGFBP3 expression.

Survival
--------

Kaplan-Meier survival analyses showed a significantly poorer overall survival in the IGF1R-positive group compared to the IGF1R-negative group (p = 0.018). Moreover, the prognosis of patients with IGF1R-positive and IGFBP3-negative PDAC was significantly poorer than that of other patients (p \< 0.001). In contrast, the prognosis of patients with IGF1R-negative and IGFBP3-positive PDAC was not significantly correlation with overall survival (*p* = 0.218), while IGFBP3 expression alone tended to be associated with overall survival (p = 0.079) (Figure  [2](#F2){ref-type="fig"}). Figure  [3](#F3){ref-type="fig"} shows the overall survival stratified for IGF1R and IGFBP3 expression in cancer cells according to clinical stage II status. The prognosis for IGF1R positive patients with stage II tumors was significantly (*p* = 0.0080) poorer than that for IGF1R negative patients, while no significant difference in the prognosis was found between the IGF1R expression in either stage I or III tumors (data not shown). On univariate analysis, three factors, IGF1R overexpression, IGF1R-positive and IGFBP3-negative expression, and lymph node metastasis, were significantly associated with worse overall survival. Because IGF1R status is deeply associated with IGF1R and IGFBP3 status, multivariate analysis was performed with two factors: IGF1R-positive and IGFBP3-negative expression, and lymph node metastasis. The multivariate survival analysis indicated that IGF1R-positive and IGFBP3-negative expression, along with lymph node metastasis, were independent prognostic indicators (Table  [3](#T3){ref-type="table"}). IGF1R-positive and IGFBP3-negative expression and lymph node metastasis were independent predictors of poor prognosis.

![**Overall survival of patients based on IGF1R and IGFBP3 expression.** The survival curve shows the Kaplan-Meier overall survival curves in relation to the IGF1R and IGFBP3 levels in patients with pancreatic cancer. A statistically significant difference in survival was observed between patients with IGF1R-positive and IGF1R-negative tumors (p = 0.018). The prognosis of patients with IGF1R-positive and IGFBP3-negative patients showed a significant correlation with overall survival (p \< 0.001). IGFBP3 expression alone tended to be associated with overall survival (p = 0.079). The co-expression of IGF1R-negative and IGFBP3-positive PDAC was not associated with overall survival (*p* = 0.218).](1471-2407-13-392-2){#F2}

![**Overall survival stratified by IGF1R and IGFBP3 expression in cancer cells in patients with clinical stage II tumors.** Prognosis of IGF1R-positive cancer was significantly poorer (p = 0.008) than that of IGF1R-negative cancer in the stage II group. Analysis of prognosis of patients with IGF1R-positive and IGFBP3-negative tumors shows a significant correlation with overall survival (p = 0.0009) in patients with stage II tumors.](1471-2407-13-392-3){#F3}

###### 

Univariate and multivariate survival analyses in pancreatic cancer

            **Variable**            **Univariate analysis**   **Multivariate analysis**                                   
  -------------------------------- ------------------------- --------------------------- ---------- ------- ------------- ----------
          IGF1R expression                                                                                                     
         Positive vs negative                1.714                   1.091-2.693           0.020                               
       IGFBP3 low expression                                                                                                   
         Positive vs negative                1.561                   0.946-2.576           0.081                               
       IGF1R (+) & IGFBP3 (−)                                                                                                  
         Positive vs negative                3.101                   1.843-5.218          \< 0.001   3.060   1.823-5.138   \< 0.001
               Gender                                                                                                          
            male vs female                   0.975                   0.623-1.525           0.911                               
                Age                                                                                                            
             ≧ 60 vs \<60                    1.444                   0.822-2.537           0.201                               
             T category                                                                                                        
              3, 4 vs 1,2                    1.844                   0.997-3.413           0.051                               
       Lymph node metastasis                                                                                                   
         Positive vs negative                1.79                    1.106-2.736           0.017     1.718   1.092-2.702    0.019
           Tumor location                                                                                                      
          proximal vs distal                 1.108                   0.671-1.736           0.752                               
         Lymphatic invasion                                                                                                    
         Positive vs negative                1.332                   0.855-2.075           0.205                               
         Arterial invasion                                                                                                     
         Positive vs negative                1.209                   0.554-2.637           0.634                               
          Venous invasion                                                                                                      
         Positive vs negative                1.579                   0.812-3.071           0.178                               
   Intrapancreatic nerve invasion                                                                                              
         Positive vs negative                1.452                   0.930-2.267           0.101                               
       Tumor differentiation                                                                                                   
        grade 1,2 vs grade 3,4               1.452                   0.826-2.551           0.195                               
        Tumor stromal volume                                                                                                   
            med/int vs scir                  0.724                   0.453-1.156           0.176                               

Discussion
==========

The present study analyzed the immunohistochemical expression of IGF1R and IGFBP3 with clinicopathological variables and the correlation with overall survival in 122 patients with PDAC. IGF1R expression had a significant association with histological grade of tumor differentiation, and also tended to be associated with abundant stroma. These findings suggest that the IGF1R signaling system might be correlated with histopathologic features of PDAC. It has been reported that IGF1 is produced from stromal cells \[[@B11]\]. There might be an interaction between cancer cells and stromal cells via IGF/IGF1R signaling. PDAC patients with IGF1R-positive expression showed significantly poorer survival, compared to the IGF1R-negative group (Figure  [2](#F2){ref-type="fig"}). The present findings suggest that the IGF1R signaling system might be correlated with tumor aggressiveness in PDAC, as has been previously reported \[[@B25],[@B26]\].

IGF bioavailability is regulated by a family of six IGF-binding proteins (IGFBP), of which IGFBP3 is the major IGF carrier protein \[[@B17]\]. The function of IGFBP3 is controversial. IGFBP3 has been shown to produce either inhibition \[[@B27]-[@B29]\] or potentiation \[[@B30]-[@B32]\] of IGF effects. The direction of the effect may depend on the cell type \[[@B27]\]. In this study, favorable survival in the IGFBP3-positive group was noted, but statistical significance was not obtained (Figure  [2](#F2){ref-type="fig"}). IGFBP3 expression had an inverse association with venous invasion. These findings suggest that IGFBP3 might show antiproliferative effects in PDAC. IGFBP3 expression had a significant association with proximal tumors. Most insulin is secreted from the distal pancreas. IGFBP3 expression might be associated with lesions involving insulin secretion.

Next, the significance of the combination of IGF1R expression and IGFBP3 expression was evaluated. Tumors with IGF1R-positive and IGFBP3-negative expression were significantly frequently found at an advanced clinical stage (II or III), compared to the other groups. The prognosis of patients with IGF1R-positive and IGFBP3-negative PDAC was poorer than that of other groups, especially in patients with stage II tumors (Figure  [3](#F3){ref-type="fig"}). The IGF1R-positive and IGFBP3-negative subgroup was the group with the worst prognosis (Figures  [2](#F2){ref-type="fig"} &[3](#F3){ref-type="fig"}). These findings suggest that IGFBP3 could produce inhibition of IGF effects. Decreased IGFBP3 production and increased IGF1R expression in pancreas tumors might enhance the tumorigenesis and cell motility as previously reported \[[@B26],[@B33],[@B34]\]. Prediction of prognosis in patients with operable PDAC is important to determine the adjuvant therapy. This is especially true in patients with stage II tumors, because the local recurrence rate of PDAC is high, even in patients with curative R0 operations. The present study suggests that combined evaluation of IGF1R expression and IGFBP3 expression is a useful prognostic factor in pancreatic cancer, especially with clinical stage II tumors.

Although IGFBP3 is the major IGF carrier protein, some paper reported that IGFBP3 has IGF-independent antiproliferative and proapoptotic effects \[[@B20],[@B21]\]. The inhibition of IGF1-induced functions by cell surface-associated IGFBP3 have been reported \[[@B27],[@B29]\]; however, the relationship between membrane-associated IGFBPs and IGF1R signaling is less well understood. Therefor significance of co-expression of IGFBP3 and IGF1R in PDAC remains obscure. We then analyzed the significance of IGF1R-negative and IGFBP3-positive group with respect to overall survival (in the right bottom diagram of Figures  [2](#F2){ref-type="fig"} &[3](#F3){ref-type="fig"}), which might clarify whether IGFBP3 is IGF1/IGF1R signaling-independent or not. Although IGFBP3 expression alone tended to be associated with overall survival (p = 0.079), co-expression of IGF1R-negative and IGFBP3-positive PDAC was not associated with overall survival (*p* = 0.218). These data suggested that the function of IGFBP3 might be dependent on IGF1R expression.

Conclusion
==========

IGF1R signaling might be associated with tumor aggressiveness, and IGFBP3 might show antiproliferative effects in pancreatic cancer. Both high IGF1R expression and low IGFBP3 expression represent useful prognostic markers for patients with curatively resected pancreatic cancer.
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